Comparative Pharmacology
Head-to-head clinical analysis: REVIA versus ZIMHI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REVIA versus ZIMHI.
REVIA vs ZIMHI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naltrexone is a mu-opioid receptor antagonist that competitively binds to opioid receptors, blocking the effects of endogenous and exogenous opioids. It also exhibits some antagonistic activity at kappa and delta opioid receptors.
Opioid receptor antagonist; reverses opioid effects by competitively binding to mu-opioid receptors.
50 mg orally once daily
5 mg intramuscularly every 2-3 minutes as needed; maximum 3 doses.
None Documented
None Documented
Terminal half-life of naltrexone is approximately 4 hours; its active metabolite, 6β-naltrexol, has a half-life of about 13 hours. Clinically, the prolonged blockade of opioid receptors (up to 72 hours after a single oral dose) is attributed to the metabolite's accumulation and high receptor affinity.
Terminal half-life: 2.5-4 hours; clinical context: short duration requires repeat dosing for sustained opioid effects.
Renal: primarily as unchanged drug and glucuronide conjugates; fecal: minor; approximately 60% of a dose is excreted in urine within 48 hours (with about 20% as unchanged naltrexone and the rest as metabolites, mainly 6β-naltrexol).
Renal: 30-35% unchanged; biliary/fecal: 50-60% as metabolites.
Category C
Category C
Opioid Antagonist
Opioid Antagonist